Disc Medicine, Inc.

Disc Medicine, Inc., trading on Nasdaq under the ticker FSDC, filed an 8-K with the Securities and Exchange Commission on June 13, 2025. FSDC represents the surviving public entity following the completion of a de-SPAC business combination, with the registrant operating as a clinical-stage biopharmaceutical company focused on developing therapies for serious hematologic diseases, placing it within the biotechnology and life sciences sector. The June 2025 filing reflects the company's continuing disclosure obligations as a public registrant following its merger close. Investors and researchers tracking SPAC deal outcomes and post-merger filings can access full transaction timelines, deal metrics, and filing histories for FSDC by signing up at SpacDesk.